Short answer
Aclaris Therapeutics, Inc. (ACRS) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $2M (up 37.2% year over year) with net income of −$20M.
Q1 2026 key financials · XBRL
- Revenue
- $2M
- +37.2% YoY
- Net income
- −$20M
- −31.4% YoY
- Operating margin
- -1111.8%
- EPS (diluted)
- −$0.15
- −25.0% YoY
Source: XBRL data from the Aclaris Therapeutics, Inc. (ACRS) Q1 2026 10-Q on SEC EDGAR. USD.
Aclaris Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- MD&A excerpt incomplete; no quarterly revenue, YoY comparison, profitability, or margin figures provided
- Segment or product-line performance unavailable in provided text
- Cash position, operating cash flow, and capital deployment figures unavailable
- Near-term outlook limited to standard forward-looking-statement risk disclosures
Risk Factors
- No risk-factors section provided in the submitted excerpt
- No newly added risk factor identifiable
- No materially updated regulatory, legal, operational, market, or financial risk disclosed
- No Rule 10b5-1 trading arrangements adopted, modified, or terminated during the quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Aclaris Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.